NasdaqCM - Nasdaq Real Time Price USD
Marker Therapeutics, Inc. (MRKR)
As of 1:18 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
466.7850
Operating Expense
10,994.9200
14,581.3780
19,791.0040
39,477.9950
28,885.8120
Operating Income
-10,994.9200
-14,581.3780
-19,791.0040
-39,477.9950
-28,419.0270
Net Non Operating Interest Income Expense
691.0080
539.1580
248.0630
5.7000
148.7420
Other Income Expense
--
--
-232.9740
-2,406.5760
31.0000
Pretax Income
-10,303.9120
-14,042.2200
-19,775.9150
-41,878.8710
-28,239.2850
Tax Provision
--
3.6750
--
--
--
Net Income Common Stockholders
-10,370.5260
-8,236.8140
-29,930.6940
-41,878.8710
-28,706.0700
Diluted NI Available to Com Stockholders
-10,370.5260
-8,236.8140
-29,930.6940
-41,878.8710
-28,706.0700
Basic EPS
-1.17
-0.94
-3.58
-5.47
-6.10
Diluted EPS
-1.17
-0.94
-3.58
-5.47
-6.10
Basic Average Shares
8,884.3260
8,809.3820
8,351.0030
7,650.5670
4,703.9860
Diluted Average Shares
8,884.3260
8,809.3820
8,351.0030
7,650.5670
4,703.9860
Total Operating Income as Reported
-10,994.9200
-14,581.3780
-19,791.0040
-39,477.9950
-28,885.8120
Total Expenses
10,994.9200
14,581.3780
19,791.0040
39,477.9950
28,885.8120
Net Income from Continuing & Discontinued Operation
-10,370.5260
-8,236.8140
-29,930.6940
-41,878.8710
-28,706.0700
Normalized Income
-10,307.5870
-14,045.8950
-19,775.9150
-41,878.8710
-28,737.0700
Interest Income
691.0080
539.1580
248.0630
5.7000
148.7420
Net Interest Income
691.0080
539.1580
248.0630
5.7000
148.7420
EBIT
-10,994.9200
-14,581.3780
-19,791.0040
-39,477.9950
-28,419.0270
EBITDA
-10,994.9200
-14,581.3780
-19,791.0040
-36,315.3570
-27,343.3470
Reconciled Depreciation
--
--
3,680.4490
3,162.6380
1,075.6800
Net Income from Continuing Operation Net Minority Interest
-10,307.5870
-14,045.8950
-19,775.9150
-41,878.8710
-28,706.0700
Total Unusual Items Excluding Goodwill
--
--
--
--
31.0000
Total Unusual Items
--
--
--
--
31.0000
Normalized EBITDA
-10,994.9200
-14,581.3780
-19,791.0040
-36,315.3570
-27,374.3470
Tax Rate for Calcs
--
0.0002
--
--
--
12/31/2020 - 7/16/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
APRE Aprea Therapeutics, Inc.
4.0000
+0.25%
SLRX Salarius Pharmaceuticals, Inc.
1.4700
-3.29%
AURA Aura Biosciences, Inc.
10.98
-0.18%
CALC CalciMedica, Inc.
3.5000
0.00%
ISCO International Stem Cell Corporation
0.0561
-43.33%
COYA Coya Therapeutics, Inc.
7.43
+2.30%
PPBT Purple Biotech Ltd
2.8998
+3.94%
OMER Omeros Corporation
4.5000
-1.10%
VINC Vincerx Pharma, Inc.
0.3300
+0.92%
LUMO Lumos Pharma, Inc.
4.3600
+1.16%